×
About 5,943 results

ALLMedicine™ Dermatomyositis Center

Research & Reviews  1,924 results

Current and new targets for treating myositis.
https://doi.org/10.1016/j.coph.2022.102257
Current Opinion in Pharmacology; Moghadam-Kia S, Oddis CV

Jun 21st, 2022 - As treatment of refractory idiopathic inflammatory myopathies (IIM) has been challenging, there is growing interest in assessing new therapies that target various pathways implicated in the pathogenesis of IIM. In the largest clinical trial to dat...

Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers.
https://doi.org/10.1007/s12016-022-08946-w 10.1016/j.autrev.2012.05.011 10.1177/1535370217750088 10.1001/jama.2016.2240 10.1038/nrrheum.2009.238 10.1002/art.39316 10.1016/j.semarthrit.2005.03.005 10.1371/journal.pone.0214202 10.1186/s13075-020-02360-3 10.1186/s13075-018-1689-6 10.1002/art.38098 10.1007/s10165-009-0155-3 10.1002/art.21232 10.1093/rheumatology/kep290 10.1002/art.10760 10.1002/art.11113 10.3899/jrheum.100316 10.1186/ar4210 10.1016/j.cca.2010.01.037 10.1136/annrheumdis-2013-203863 10.1177/0961203316644337 10.1136/annrheumdis-2018-213440 10.3389/fimmu.2020.607541 10.1093/rheumatology/keaa831 10.1002/art.38428 10.1002/art.11113 10.1002/art.24038 10.1016/j.semarthrit.2014.11.006 10.1002/art.1780340111 10.1016/j.autrev.2008.06.010 10.1073/pnas.84.14.4979 10.1016/j.autrev.2010.09.025 10.3899/jrheum.120264 10.1016/B978-0-444-56378-1.00021-6 10.1093/rap/rky002 10.3899/rheum.111133 10.1136/ard.2006.062901 10.1016/0002-9343(80)90462-3 10.1016/j.semarthrit.2015.06.011 10.1186/ar3495 10.1007/s10067-014-2616-0 10.1016/S0021-9258(19)86738-8 10.1126/science.3003910 10.1073/pnas.74.9.3800 10.1016/S0092-8674(80)80046-8 10.1002/1529-0131(199906)42:6<1179::AID-ANR14>3.0.CO;2-E 10.1006/excr.2000.4864 10.1136/annrheumdis-2018-214436 10.1136/annrheumdis-2011-200742 10.1002/art.34482 10.1097/MD.0000000000008980 10.1111/j.1365-2133.2007.08392.x 10.1002/art.1780370111 10.1371/journal.pone.0163894 10.1136/annrheumdis-2015-207271 10.1097/MD.0b013e31829be125 10.1093/rheumatology/kew298 10.1002/art.38390 10.1186/ar3125 10.1186/ar2622 10.1002/art.10977 10.1186/s13075-016-0993-2 10.1093/rheumatology/kez005 10.1002/art.41403 10.1002/art.1780360405 10.1080/2162402X.2019.1588084 10.1002/wrna.9 10.1002/art.10673 10.1016/j.revmed.2019.12.020 10.1136/ard.61.9.842 10.1186/ar2276 10.3899/jrheum.131450 10.1111/j.1756-185X.2011.01688.x 10.1007/s10067-011-1751-0 10.1002/art.1780331210 10.1136/ard.62.2.97 10.1172/JCI116343 10.7326/0003-4819-119-10-199311150-00007 10.1093/rheumatology/37.1.15 10.3899/jrheum.170037 10.1002/1529-0131(199902)42:2<275::AID-ANR9>3.0.CO;2-P 10.1002/art.10521 10.1093/rheumatology/ken201 10.1177/2397198318786158 10.1002/art.38219 10.1136/ard.2009.127621 10.3899/jrheum.160817 10.1016/j.autrev.2009.02.002 10.1097/BOR.0b013e3283588dcf 10.1136/annrheumdis-2017-211912 10.1007/s40674-016-0050-y 10.3899/jrheum.091048 10.1002/art.38994 10.3899/jrheum.080806 10.3899/jrheum.130386 10.1002/art.27549 10.3899/jrheum.101144 10.1186/ar3544 10.1186/ar4486 10.1002/art.39022 10.1002/art.38928 10.1126/science.1246886 10.1002/art.40893 10.1097/SLA.0000000000002990 10.1111/1346-8138.13292 10.55563/clinexprheumatol/mg0paj 10.1007/s00296-017-3654-0 10.3899/jrheum.160867 10.1172/JCI110295 10.1097/MD.0000000000004713 10.1007/s00018-021-03801-1 10.1136/ard.2007.073981 10.1111/pde.14243 10.1111/j.1768-322x.1985.tb00387.x 10.1002/art.1780300709 10.1002/art.1780350114 10.1002/art.24409 10.1111/sji.12510 10.3899/jrheum.160574 10.1084/jem.174.5.1239 10.1080/08916934.2017.1357699 10.1016/j.autrev.2011.03.001 10.1186/1740-2557-6-2 10.1046/j.1365-2249.1997.4081308.x 10.1016/j.semarthrit.2011.09.008 10.1016/j.autrev.2011.03.004 10.1080/03009742.2021.1887927 10.1016/j.autrev.2007.01.013 10.1097/00005792-199211000-00001 10.1002/art.1780351014 10.1186/ar2614 10.1016/j.semarthrit.2014.07.002 10.3109/08916934.2015.1077231 10.1212/WNL.0000000000005638 10.1016/j.cca.2010.03.018 10.1093/rheumatology/keab152 10.1093/rheumatology/kew382 10.1016/j.autrev.2017.03.012 10.1042/BJ20150828 10.1042/BST20051487 10.1002/art.39755 10.3109/08923973.2011.572262 10.1093/rheumatology/kex458 10.1016/j.jtauto.2020.100049 10.1016/j.chembiol.2019.12.005 10.1016/j.molcel.2009.05.016 10.1002/acr.22163 10.1006/bbrc.1998.8504 10.1002/art.24586 10.1128/mcb.12.3.1276 10.1073/pnas.90.14.6781 10.1002/acr.23763 10.1093/rheumatology/keab279 10.1002/art.37969 10.1002/art.40065 10.1093/emboj/cdg592 10.1073/pnas.1712033114 10.1016/j.autrev.2018.01.006 10.1007/s001090100258 10.1016/s1521-6616(03)00037-8 10.3899/jrheum.190945 10.1001/archderm.1961.01580150005001 10.3389/fimmu.2019.01487 10.1001/jamadermatol.2013.4207 10.1002/art.1780260506 10.1002/art.1780360815 10.1111/j.1365-2133.2004.06256.x 10.1002/art.21264 10.1111/bjd.17312 10.21037/atm-20-6222
Clinical Reviews in Allergy & Immunology; Cavazzana I, Vojinovic T et. al.

Jun 19th, 2022 - Disease-specific autoantibodies are considered the most important biomarkers for systemic sclerosis (SSc), due to their ability to stratify patients with different severity and prognosis. Anti-nuclear antibodies (ANA), occurring in subjects with i...

Two Distinct Immune Cell Signatures Predict the Clinical Outcomes in Patients with Amyo...
https://doi.org/10.1002/art.42264
Arthritis & Rheumatology (Hoboken, N.J.); Ye Y, Zhang X et. al.

Jun 18th, 2022 - Amyopathic dermatomyositis (ADM) is a heterogeneous and life-threatening autoimmune disease with high mortality. In particular, anti-MDA5 antibody-positive patients are at high risk of developing rapidly progressive interstitial lung disease (ILD)...

Combination therapy of tacrolimus, high doses of glucocorticosteroids, and cyclophospha...
https://doi.org/10.1097/MD.0000000000029108
Medicine Li L, Li M et. al.

Jun 18th, 2022 - The high-dose glucocorticosteroid (GC) treatment is the first choice for dermatomyositis complicated with interstitial lung disease (DM-ILD) but patients are resistant to the high-dose GC monotherapy. Besides, the high dose of GC, the secondary im...

A Study In Adults With Moderate To Severe Dermatomyositis
https://clinicaltrials.gov/ct2/show/NCT03181893

Jun 16th, 2022 - A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis

see more →

Guidelines  3 results

Treatment consensus for management of polymyositis and dermatomyositis among rheumatolo...
https://doi.org/10.1111/1346-8138.14604
The Journal of Dermatology; Kohsaka H, Mimori T et. al.

Dec 19th, 2018 - Although rheumatologists, neurologists and dermatologists see patients with polymyositis (PM) and dermatomyositis (DM), their management appears to vary depending on the physician's specialty. The aim of the present study was to establish the trea...

2016 American College of Rheumatology/European League Against Rheumatism Criteria for M...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517365
Annals of the Rheumatic Diseases; Rider LG, Aggarwal R et. al.

Apr 8th, 2017 - To develop response criteria for juvenile dermatomyositis (DM). We analysed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheum...

2016 American College of Rheumatology/European League Against Rheumatism criteria for m...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496443
Annals of the Rheumatic Diseases; Aggarwal R, Rider LG et. al.

Apr 8th, 2017 - To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement ...

see more →

Drugs  203 results see all →

Clinicaltrials.gov  30 results

A Study In Adults With Moderate To Severe Dermatomyositis
https://clinicaltrials.gov/ct2/show/NCT03181893

Jun 16th, 2022 - A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
https://clinicaltrials.gov/ct2/show/NCT03816345

Jun 8th, 2022 - PRIMARY OBJECTIVE: I. To assess the overall safety, including the incidence of dose-limiting toxicity (DLT), and other toxicities associated with the use of the anti-programmed death 1 (PD-1) antibody nivolumab in patients with varying severity of...

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
https://clinicaltrials.gov/ct2/show/NCT04999020

Jun 3rd, 2022 - The study will be conducted in 2 parts: Part A (Phase 2) and Part B (Phase 3). There will be 3 periods in both Part A and Part B of this study: Screening Period, Randomized Controlled Period, and Open-Label Extension Period.

Chronic Transcranial Direct Current Stimulation in Patients With Systemic Autoimmune Myopathies
https://clinicaltrials.gov/ct2/show/NCT04678635

Jun 3rd, 2022 - Systemic autoimmune myopathies are rheumatic diseases that affect the striatum skeletal muscles. Depending on the clinical, pathophysiological and laboratory characteristics, they may be subdivided into polymyositis, dermatomyositis, antissintetas...

Gastric Mucosal Changes in Patients With Dermatomyositis
https://clinicaltrials.gov/ct2/show/NCT05402670

Jun 2nd, 2022 - There are a large number of reports in the literature that patients with dermatomyositis often have various malignant tumors, and reports of gastric cancer are not rare. At present, the widely recognized gastric cancer occurrence patterns are: nor...

see more →

News  208 results

Lenabasum Improved Skin Symptoms in Dermatomyositis, but Future Is Uncertain
https://www.medscape.com/viewarticle/974012

May 13th, 2022 - An investigative synthetic cannabinoid receptor type 2 (CB2) agonist, lenabasum, was associated with greater improvements than placebo in patients with skin-predominant dermatomyositis — some of it statistically significant — in a phase 2 double-b...

Unique Dermatology Residency Track Focuses on Rural Placement of Graduates
https://www.medscape.com/viewarticle/973788

May 11th, 2022 - BOSTON – As a former active-duty cavalry officer in the U.S. Army who served a 15-month tour in Iraq in 2003, Adam C. Byrd, MD, isn't easily rattled. On any given day, as the only dermatologist in his hometown of Louisville, Miss., which has a pop...

Fast Five Quiz: Progressive Fibrosing Interstitial Lung Disease
https://www.medscape.com/viewarticle/969959

Apr 12th, 2022 - Interstitial lung diseases (ILDs) encompass a large and varied group of parenchymal lung disorders, including diseases of unknown cause, which are known as idiopathic interstitial pneumonias, as well as those associated with other diseases or envi...

Bilateral palmar rash
https://www.mdedge.com/familymedicine/article/253507/dermatology/bilateral-palmar-rash
MDedge Family Medicine;

Apr 6th, 2022 - A biopsy was performed and the pathology report showed ectatic, thin-walled vessels consistent with telangiectasias. There were no other inflammatory, infectious, or malignant changes.

see more →

Patient Education  9 results see all →